Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model

Journal of Virology

Volumn 88, Issue 18, 2014, Pages 10421-10431

  Wu, Jun ^a   Huang, Shunmei ^a   Zhao, Xiaoli ^a   Chen, Mingfa ^a   Lin, Yong ^a   Xia, Youchen ^a   Sun, Chan ^a   Yang, Xuecheng ^a   Wang, Junzhong ^a   Guo, Yan ^a   Song, Jingjiao ^a   Zhang, Ejuan ^b   Wang, Baoju ^a   Zheng, Xin ^a   Schlaak, Joerg F ^b   Lu, Mengji ^b   Yang, Dongliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON RECEPTOR; CELL MARKER; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS B; HYDRODYNAMICS; IMMUNOMODULATION; IN VIVO STUDY; INTERFERON PRODUCTION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS REPLICATION; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; LIVER; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; HYDRODYNAMICS; INTERFERONS; LIVER; MICE; MICE, INBRED C57BL; VIRUS REPLICATION;

EID: 84906337676     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00996-14     Document Type: Article

References (43)

1. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
2. Isogawa M, Robek MD, Furuichi Y, Chisari FV. 2005. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79:7269- 7272. http://dx.doi.org/10.1128/JVI.79.11.7269-7272.2005.
3. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF. 2007. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46:1769-1778. http://dx.doi.org/10.1002/hep.21897.
4. Wu J, Chen MF, Xia YC, Guo Y, Lin Y, Sun C, Zhang CY, Chen Y, Liu SP, Hao YH. 2011. Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control ofHBVreplication. Zhonghua Gan Zang Bing Za Zhi 19:838-842. (In Chinese.) http://dx.doi .org/10.3760/cma.j.issn.1007-3418.2011.11.011.
5. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M. 2012. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J. Hepatol. 57:522-528. http://dx .doi.org/10.1016/j.jhep.2012.05.004.
6. Zhang X, Meng Z, Qiu S, Xu Y, Yang D, Schlaak JF, Roggendorf M, Lu M. 2009. Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell. Microbiol. 11:1624-1637. http://dx.doi.org/10.1111/j.1462-5822.2009.01353.x.
7. Wilkins C, Gale M, Jr. 2010. Recognition of viruses by cytoplasmic sensors. Curr. Opin. Immunol. 22:41-47. http://dx.doi.org/10.1016/j.coi .2009.12.003.
8. Kawai T, Akira S. 2007. Antiviral signaling through pattern recognition receptors. J. Biochem. 141:137-145.
9. Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511. http://dx.doi.org/10.1038/nri1391.
10. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981-988. http://dx.doi.org/10.1038/ni1243.
11. Kawai T, Akira S. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20. http://dx.doi.org/10.1196/annals .1443.020.
12. Kondo Y, Ueno Y, Ninomiya M, Tamai K, Tanaka Y, Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T. 2012. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. J. Gastroenterol. 47:1323-1335. http://dx.doi.org/10.1007/s00535-012-0596-x.
13. Huang LR, Wu HL, Chen PJ, Chen DS. 2006. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 103:17862-17867. http://dx.doi.org/10 .1073/pnas.0608578103.
14. Detre S, Saclani JG, Dowsett M. 1995. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48:876-878. http://dx.doi.org/10 .1136/jcp.48.9.876.
15. Guan SH, Lu M, Grunewald P, Roggendorf M, Gerken G, Schlaak JF. 2007. Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment. World J. Gastroenterol. 13:228-235. http://dx.doi.org/10.3748/wjg.v13.i2.228.
16. Rehermann B. 2003. Immune responses in hepatitis B virus infection. Semin. Liver Dis. 23:21-38. http://dx.doi.org/10.1055/s-2003-37586.
17. Gibbert K, Dietze KK, Zelinskyy G, Lang KS, Barchet W, Kirschning CJ, Dittmer U. 2010. Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J. Immunol. 185:6179-6189. http://dx.doi.org/10.4049/jimmunol.1000858.
18. Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, Chisari FV. 2002. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J. Virol. 76:2617-2621. http: //dx.doi.org/10.1128/JVI.76.6.2617-2621.2002.
19. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36. http://dx.doi.org/10.1016/S1074-7613 (00)80295-2.
20. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadiere C, Chaput N, Andre F, Kroemer G, Zitvogel L. 2010. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70:490-500. http://dx.doi.org/10.1158/0008-5472.CAN-09-1890.
21. Ijichi K, Mitamura K, Ida S, Machida H, Shimada K. 1994. In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus. J. Med. Virol. 43:161-165. http://dx.doi.org/10.1002/jmv .1890430212.
22. Niu J, Wang Y, Dixon R, Bowden S, Qiao M, Einck L, Locarnini S. 1993. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res. 21:155-171. http://dx.doi.org/10 .1016/0166-3542(93)90051-J.
23. Drugs R. D. 2004. Mismatched double-stranded RNA: polyI:polyC12U. Drugs R. D. 5:297-304. http://dx.doi.org/10.2165/00126839-200405050 -00006.
24. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, Chisari FV. 2009. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83:9652-9662. http: //dx.doi.org/10.1128/JVI.00867-09.
25. Honke N, Shaabani N, Cadeddu G, Sorg UR, Zhang DE, Trilling M, Klingel K, Sauter M, Kandolf R, Gailus N, RNvan Burkart C, Baldus SE, Grusdat M, Lohning M, Hengel H, Pfeffer K, Tanaka M, Haussinger D, Recher M, Lang PA, Lang KS. 2012. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat. Immunol. 13:51-57. http://dx.doi.org/10.1038/ni.2169.
26. Wu J, Meng Z, Jiang M, Zhang E, Trippler M, Broering R, Bucchi A, Krux F, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. 2010. Toll-like receptor-induced innate immune responses in nonparenchymal liver cells are cell type-specific. Immunology 129:363-374. http://dx.doi.org/10.1111/j.1365-2567.2009.03179.x.
27. Sun R, Zhang Y, Lv Q, Liu B, Jin M, Zhang W, He Q, Deng M, Liu X, Li G, Li Y, Zhou G, Xie P, Xie X, Hu J, Duan Z. 2011. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by upregulating the transactivating p63 isoform alpha (TAP63alpha). J. Biol. Chem. 286:15918-15928. http://dx.doi.org/10.1074/jbc.M110.178798.
28. Liew FY, Xu D, Brint EK, O'Neill LA. 2005. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5:446-458. http://dx.doi.org/10.1038/nri1630.
29. Bahl K, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Selin LK, Welsh RM. 2006. IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J. Immunol. 176:4284-4295. http://dx.doi.org/10.4049/jimmunol.176.7.4284.
30. McNally JM, Zarozinski CC, Lin MY, Brehm MA, Chen HD, Welsh RM. 2001. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J. Virol. 75:5965-5976. http://dx.doi.org/10 .1128/JVI.75.13.5965-5976.2001.
31. Bahl K, Huebner A, Davis RJ, Welsh RM. 2010. Analysis of apoptosis of memory T cells and dendritic cells during the early stages of viral infection or exposure to toll-like receptor agonists. J. Virol. 84:4866-4877. http: //dx.doi.org/10.1128/JVI.02571-09.
32. Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF. 2008. Toll-like receptor-stimulated nonparenchymal liver cells can regulate hepatitis C virus replication. J. Hepatol. 48:914-922. http://dx.doi.org/10.1016/j.jhep.2008.01.028.
33. Wang B, Trippler M, Pei R, Lu M, Broering R, Gerken G, Schlaak JF. 2009. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J. Hepatol. 51:1037- 1045. http://dx.doi.org/10.1016/j.jhep.2009.06.020.
34. Tough DF. 2004. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk. Lymphoma 45:257- 264. http://dx.doi.org/10.1080/1042819031000149368.
35. Le BA, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF. 2003. Cross-priming of CD8_ T cells stimulated by virusinduced type I interferon. Nat. Immunol. 4:1009-1015. http://dx.doi.org /10.1038/ni978.
36. Tough DF. 2012. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90:492-497. http://dx.doi.org/10.1038/icb.2012.7.
37. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK. 2010. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6:e1001227. http://dx .doi.org/10.1371/journal.ppat.1001227.
38. Tu Z, Hamalainen-Laanaya HK, Crispe IN, Orloff MS. 2011. Synergy between TLR3 and IL-18 promotes IFN-gamma dependent TRAIL expression in human liver NK cells. Cell. Immunol. 271:286-291. http://dx .doi.org/10.1016/j.cellimm.2011.07.006.
39. Duluc D, Tan F, Scotet M, Blanchard S, Fremaux I, Garo E, Horvat B, Eid P, Delneste Y, Jeannin P. 2009. PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by humanNKcells via autocrine IFN-beta. Eur. J. Immunol. 39:2877-2884. http://dx.doi.org/10.1002/eji.200838610.
40. Gardner TR, Chen Q, Jin Y, Ajuebor MN. 2010. Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells. Am. J. Pathol. 176:1779-1789. http://dx.doi.org/10.2353/ajpath.2010.090738.
41. Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM. 2001. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33:448-454. http://dx.doi.org/10.1053/jhep.2001.21594.
42. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. 1996. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97:1655-1665. http://dx.doi.org/10.1172/JCI118592.
43. Guidotti LG, McClary H, Loudis JM, Chisari FV. 2000. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J. Exp. Med. 191:1247-1252. http://dx.doi.org/10.1084/jem.191.7.1247.